More Innovative Hypertension Treatments On The Horizon As Patents Expire In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - A Daiichi Sankyo announcement that its hypertension treatment, olmesartan (Benicar in the United States), has demonstrated effectiveness for preventing or reversing the narrowing of arteries in high blood-pressure patients may be a precursor to a rash of Japanese drug makers' similar findings in the coming months as the patents of many of their globally-distributed products expire around 2010, a securities company strategist said June 20